China Pharma Holdings, Inc. — Q1 2013 Form 10-Q
Business context and reporting period. The filing covers the three months ended March 31, 2013. The company develops, manufactures and markets pharmaceutical products in China through its wholly owned subsidiary, Helpson. Financial statements are unaudited; results for the quarter are not necessarily indicative of full-year results.
Key financial results
| Metric | Q1 2013 | Q1 2012 / comparison |
|---|---|---|
| Revenue | $8.25 million | $16.09 million; down 49% |
| Gross profit (loss) | $(1.57) million; gross margin (19%) | $5.30 million; gross margin 33% |
| Operating income (loss) | $(3.00) million | $3.41 million |
| Net income (loss) | $(2.81) million; $(0.06) per diluted share | $2.81 million; $0.06 per diluted share |
| Operating cash flow | $1.11 million provided | $0.40 million provided |
| Investing cash flow | $0.40 million used | $1.08 million used |
| Cash and cash equivalents | $4.75 million at March 31 | $4.03 million at December 31, 2012 |
| Current assets / current liabilities | $108.22 million / $12.63 million | $112.53 million / $14.63 million at December 31, 2012 |
Cost of revenue was $6.13 million, or 74.3% of revenue. Including the $3.69 million Buflomedil inventory write-off, gross loss was $1.57 million. Management estimates gross profit would have been approximately $2.1 million, or a 26% margin, without that charge. Selling expenses were $0.81 million, general and administrative expenses $0.74 million, and net interest expense $0.08 million. The company recorded a $0.27 million income tax benefit.
Cash increased by $0.72 million during the quarter. The company reported $4.79 million of short-term bank notes outstanding, bearing 6.90% interest and collateralized by certain land-use rights, buildings and receivables; no additional amount was available under the credit line. It also owed a board member $1.35 million, bearing 1% interest. No cash flow was generated from financing activities.
Material changes and unusual items
- Revenue fell across all reported product categories. Management attributed the decline to tighter control of customer credit to support GMP-upgrade spending, industry and pricing pressures, and the cessation of Buflomedil sales.
- In March 2013, China’s CFDA ordered production, sale and use of Buflomedil to cease. The company stopped production and sales, recalled products, wrote off $3.69 million of related inventory, and recorded $21,507 of customer refunds as a reduction of revenue. The CFDA revoked the related production licenses; the company reported no remaining carrying value for related intangible assets.
- Receivables were $62.70 million, down from $66.18 million at year-end, but $52.8 million was more than 90 days past due. The allowance for doubtful accounts was $4.33 million. Management said customers, primarily distributors serving government-backed hospitals, generally pay late and stated that it had historically collected its receivables.
- Inventory was $33.26 million, down from $36.36 million at year-end, partly because of the Buflomedil write-off. One supplier accounted for 34% of first-quarter raw-material purchases. One customer represented 10.5% of receivables at quarter-end; no customer represented more than 10% of quarterly sales.
- Operating cash flow included collections in bankers’ acceptances, which are not treated as cash equivalents when maturity exceeds 90 days. Management stated that CFO would have been $2.18 million if such acceptances had received cash-equivalent treatment.
Outlook, commitments and risks
- Management believed operating cash flow and anticipated bank financing for capital expenditures would cover working capital and planned spending for the next 12 months, but warned that failure to meet its operating plan could require additional capital or spending reductions. Additional financing is not assured.
- The company had approximately $6.52 million of milestone-based obligations for medical-formula approvals, expected to be paid over roughly four years. Construction and equipment agreements carried future minimum commitments of $14.10 million: $13.13 million in 2013 and $0.97 million in 2014.
- Two injectable product lines were to be upgraded to new GMP standards by the end of 2013; construction and equipment work was underway. Delays or cost increases could pressure liquidity.
- Management planned to launch Candesartan during 2013 after receiving CFDA production approval in November 2012. The antibiotic combination remained in Phase II trials; Rosuvastatin production approval had been applied for; and a coronary heart disease medicine was in Phase III trials, with completion anticipated in 2013. CFDA approval processes were taking longer, and outcomes and timing are uncertain.
- Management expected continued pricing and gross-margin pressure, while suggesting new products could support margins after launch. The company’s revenue and operations are concentrated in China; RMB conversion and remittance abroad require government approval. PRC income tax was 15% in 2013 under the company’s high-tech designation, with a stated 25% rate for 2014 and later.
- The company reported no off-balance-sheet arrangements. Management concluded disclosure controls were effective, while noting that accounting consultants were retained to assist with inventory-obsolescence and long-lived-asset impairment reporting after a material weakness had been identified in the prior annual report.
Important facts for investors to verify
- Whether the Buflomedil recall and write-off fully capture the financial and commercial effects of the CFDA action.
- Receivable aging, subsequent collections, and the adequacy of the allowance, given that most receivables were over 90 days old.
- Progress and total funding needs for GMP upgrades, including the $14.10 million contracted commitments and availability of anticipated bank financing.
- Milestone progress and refund rights for the $6.52 million of formula-approval advances and obligations.
- Regulatory progress and launch timing for Candesartan, Rosuvastatin and pipeline products, alongside continuing pricing and raw-material cost pressures.
- Cash availability at the parent level, including PRC restrictions on currency conversion, remittance and distributions from the subsidiary.